These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J; Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099 [TBL] [Abstract][Full Text] [Related]
46. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. van der Lugt J; Colbers A; Molto J; Hawkins D; van der Ende M; Vogel M; Wyen C; Schutz M; Koopmans P; Ruxrungtham K; Richter C; Burger D; Antivir Ther; 2009; 14(3):443-50. PubMed ID: 19474478 [TBL] [Abstract][Full Text] [Related]
47. Roche issues drug interaction warning. AIDS Alert; 2005 Apr; 20(4):48. PubMed ID: 15841532 [No Abstract] [Full Text] [Related]
48. Saquinavir/Ritonavir: its evolution and current treatment role. O'Brien WA AIDS Read; 2006 Jan; 16(1):38-44; discussion 43. PubMed ID: 16433471 [TBL] [Abstract][Full Text] [Related]
49. FDA notifications. Generic lopinavir/ritonavir approved by FDA. AIDS Alert; 2009 May; 24(5):59. PubMed ID: 19452652 [No Abstract] [Full Text] [Related]
50. Amprenavir approved. AIDS Patient Care STDS; 1999 Jul; 13(7):438. PubMed ID: 10870601 [No Abstract] [Full Text] [Related]
51. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections. Tan D; Walmsley S Expert Rev Anti Infect Ther; 2007 Feb; 5(1):13-28. PubMed ID: 17266450 [TBL] [Abstract][Full Text] [Related]
52. Anti-HIV agents. A protease-only regimen--Kaletra and saquinavir. TreatmentUpdate; 2004; 16(3):8. PubMed ID: 17216837 [No Abstract] [Full Text] [Related]
53. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study. Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850 [TBL] [Abstract][Full Text] [Related]
54. Saquinavir switch study stopped. Treat Rev; 1997 Apr; (No 24):6. PubMed ID: 11364285 [TBL] [Abstract][Full Text] [Related]
55. FDA clearance for ritonavir in children with AIDS. AIDS Patient Care STDS; 1997 Jun; 11(3):194. PubMed ID: 11361797 [No Abstract] [Full Text] [Related]
56. [When nucleoside analogs cannot be tolerated. HIV therapy with booster]. MMW Fortschr Med; 2002 May; 144(19):64. PubMed ID: 12116561 [No Abstract] [Full Text] [Related]
57. Anti-HIV agents. Saquinavir--switching from Fortovase to Invirase. TreatmentUpdate; 2004; 16(3):8-9. PubMed ID: 17219608 [No Abstract] [Full Text] [Related]
58. Darunavir now approved for use in treatment-naive patients. Sax PE AIDS Clin Care; 2008 Dec; 20(12):102. PubMed ID: 19271337 [No Abstract] [Full Text] [Related]